Rakuten Securities Inc. Has $249,000 Stock Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Rakuten Securities Inc. increased its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 90.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 20,575 shares of the company’s stock after buying an additional 9,750 shares during the period. Rakuten Securities Inc.’s holdings in Elanco Animal Health were worth $249,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Jupiter Asset Management Ltd. increased its position in Elanco Animal Health by 162.1% in the fourth quarter. Jupiter Asset Management Ltd. now owns 1,374,464 shares of the company’s stock worth $16,645,000 after buying an additional 849,977 shares during the last quarter. Channing Capital Management LLC grew its stake in shares of Elanco Animal Health by 5.8% in the fourth quarter. Channing Capital Management LLC now owns 731,769 shares of the company’s stock worth $8,862,000 after purchasing an additional 40,359 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Elanco Animal Health by 9.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 117,611 shares of the company’s stock valued at $1,424,000 after purchasing an additional 9,928 shares during the period. Callan Family Office LLC purchased a new position in shares of Elanco Animal Health during the fourth quarter valued at approximately $445,000. Finally, Vestmark Advisory Solutions Inc. raised its stake in shares of Elanco Animal Health by 14.3% in the fourth quarter. Vestmark Advisory Solutions Inc. now owns 30,586 shares of the company’s stock worth $370,000 after purchasing an additional 3,826 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Stifel Nicolaus lowered their price target on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, February 21st. Leerink Partnrs raised shares of Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. UBS Group lowered their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Leerink Partners began coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They set a “market perform” rating and a $14.00 price objective for the company. Finally, Morgan Stanley decreased their price objective on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a report on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Elanco Animal Health has a consensus rating of “Hold” and a consensus price target of $15.17.

Insider Buying and Selling

In other Elanco Animal Health news, Director Lawrence Erik Kurzius bought 10,000 shares of the company’s stock in a transaction dated Tuesday, March 11th. The shares were acquired at an average cost of $10.20 per share, with a total value of $102,000.00. Following the completion of the transaction, the director now owns 111,459 shares in the company, valued at $1,136,881.80. The trade was a 9.86 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.57% of the company’s stock.

Elanco Animal Health Stock Down 6.8 %

Shares of NYSE ELAN opened at $10.07 on Wednesday. The business has a 50-day moving average price of $11.56 and a 200 day moving average price of $12.83. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The stock has a market cap of $4.98 billion, a PE ratio of 25.16, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44. Elanco Animal Health Incorporated has a 52-week low of $10.03 and a 52-week high of $18.80.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same period last year, the company posted $0.08 EPS. Equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.